APA (7th ed.) Citation

Byrd, J. C., Pagel, J. M., Awan, F. T., Forero, A., Flinn, I. W., Deauna-Limayo, D. P., . . . Furman, R. R. (2014). A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood, 123(9), 1302-1308. https://doi.org/10.1182/blood-2013-07-512137

Chicago Style (17th ed.) Citation

Byrd, John C., et al. "A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab, an Anti-CD37 Mono-specific ADAPTIR Therapeutic Protein in Chronic Lymphocytic Leukemia." Blood 123, no. 9 (2014): 1302-1308. https://doi.org/10.1182/blood-2013-07-512137.

MLA (9th ed.) Citation

Byrd, John C., et al. "A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab, an Anti-CD37 Mono-specific ADAPTIR Therapeutic Protein in Chronic Lymphocytic Leukemia." Blood, vol. 123, no. 9, 2014, pp. 1302-1308, https://doi.org/10.1182/blood-2013-07-512137.